Free Account Opening + AMC Free Demat
Loading...

Nuvoco IPO vs Windlas Biotech IPO

Comparision between Nuvoco IPO and Windlas Biotech IPO.

IPO Details

Nuvoco IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Windlas Biotech IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.

Issue Size and Price

The total issue size of Nuvoco IPO is up to ₹5,000.00 Cr whereas the issue size of the Windlas Biotech IPO is up to ₹401.54 Cr. The final issue price of Nuvoco IPO is ₹570.00 per share and of Windlas Biotech IPO is ₹460.00 per share.

  Nuvoco IPO Windlas Biotech IPO
Face Value ₹10 per share ₹5 per share
Issue Price (Lower) ₹560.00 per share ₹448.00 per share
Issue Price (Upper) ₹570.00 per share ₹460.00 per share
Issue Price (Final) ₹570.00 per share ₹460.00 per share
Discount (Retail)
Discount (Employee)
Market Lot Size 26 shares 30 shares
Fresh Issue Size
Fresh Issue Size (Amount) up to ₹1,500.00 Cr up to ₹165.00 Cr
OFS Issue Size 51,42,067 shares
OFS Issue Size (Amount) up to ₹3,500.00 Cr up to ₹236.54 Cr
Issue Size Total
Issue Size Total (Amount) up to ₹5,000.00 Cr up to ₹401.54 Cr

IPO Timetable

Nuvoco IPO opens on Aug 09, 2021, while Windlas Biotech IPO opens on Aug 04, 2021. The closing date of Nuvoco IPO and Windlas Biotech IPO is Aug 11, 2021, and Aug 06, 2021, respectively.

  Nuvoco IPO Windlas Biotech IPO
Anchor Bid Date
Issue Open Aug 09, 2021 Aug 04, 2021
Issue Close Aug 11, 2021 Aug 06, 2021
Basis Of Allotment (Tentative) Aug 17, 2021 Aug 11, 2021
Initiation of Refunds (Tentative) Aug 18, 2021 Aug 12, 2021
Credit of Share (Tentative) Aug 20, 2021 Aug 13, 2021
Listing date (Tentative) Aug 23, 2021 Aug 16, 2021
Anchor Lockin End date 1 Sep 16, 2021 Sep 10, 2021
Anchor Lockin End date 2 Nov 15, 2021 Nov 09, 2021

Financials

Nuvoco IPO P/E ratio is , as compared to Windlas Biotech IPO P/E ratio of .

  Nuvoco IPO Windlas Biotech IPO
Financial
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (₹ in million)
31-Mar-21 31-Mar-20 31-Mar-19
Total Assets 1,99,075.70 134,443.22 132,617.03
Total Revenue 75,226.93 68,299.44 71,058.88
Profit After Tax (259.19) 2,492.55 (264.88)
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (₹ in million)
31-Mar-21 31-Mar-20 31-Mar-19
Total Assets 2,961.23 3,384.88 2,981.80
Total Revenue 4,306.95 3,313.39 3,115.25
Profit After Tax 155.70 162.13 638.22
Promoter Shareholding (Pre-Issue) 95.24% 78%
Promoter Shareholding (Post-Issue) 71.03% 65.16%
P/E Ratio
Market Cap
ROE
ROCE
Debt/Equity
EPS
RoNW

Shares Offered

In the Nuvoco IPO retail investors (RII) are offered 3,12,50,000 shares while in Windlas Biotech IPO retail investors are offered 3,12,50,000 shares. Qualified institutional buyers (QIB) are offered 1,78,57,143 shares in Nuvoco IPO and 17,23,700 shares in Windlas Biotech IPO.

  Nuvoco IPO Windlas Biotech IPO
Anchor Investor Reserveration
Market Maker Reserveration
QIB 1,78,57,143 shares 17,23,700 shares
NII 1,33,92,858 shares 13,23,766 shares
RII 3,12,50,000 shares 30,88,786 shares
Employee 0 shares 0 shares
Others
Total 6,25,00,001 shares 61,36,252 shares

Bids Received (Subscription)

Nuvoco IPO subscribed 1.71x in total, whereas Windlas Biotech IPO subscribed 22.44x.

  Nuvoco IPO Windlas Biotech IPO
QIB (times) 4.23x 24.40x
NII (times) 0.66x 15.73x
Big NII (times)
Small NII (times)
RII (times) 0.73x 24.22x
Employee (times)
Other (times)
Total (times) 1.71x 22.44x

Comments

Add a public comment...